ILiAD Biotechnologies
Weston, FL, United States · Biotechnology · 25 employees
ILiAD Biotechnologies is a [Phase 3 ready] clinical-stage biotech company dedicated to the prevention and treatment of human disease caused by Bordetella pertussis and other respiratory diseases.
Funding history
- Funding Round — $115.5M — Feb 2026
- Series series b — $115.0M — Feb 2026
- Series seed — $3.0M — Oct 2022
- Funding Round — $42.8M — Sep 2022
- Funding Round — $42.8M — Sep 2022
Recent signals
- Feb 20, 2026: Raised $115.5M
- Feb 10, 2026: Raised $115.0M in Series series b
- Dec 04, 2024: Launched ILiAD Biotechnologies Announces Innovation Passport Designation for BPZE1 Next Generation Intranasal Pertussis Vaccine
- Oct 25, 2022: Raised $3.0M in Series seed
- Sep 06, 2022: Raised $42.8M
- Sep 06, 2022: Raised $42.8M
- Mar 03, 2021: Raised Undisclosed
- Mar 31, 2020: Raised $4.3M in Series seed
See plans & pricing → Track ILiAD Biotechnologies’s funding, hiring, and signals — with verified contacts — on Fundz.